Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

AIM ImmunoTech Inc.

  • OCALA, Florida
  • Public · NYSE: AIM
  • 21 employees
$7.5MMarket cap
$88.0KRevenue · FY2025
-$14.0MNet income
21Employees
AIMNYSE
1995IPO

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$88.0K
Net income
-$14.0M
Total assets
$5.8M
Market cap
$7.5M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: AIM

15-minute delayed · data by Polygon.io

Market cap
$7.5M
Open
Day range
Prev close
Volume
IPO date
Nov 2, 1995

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review AIM ImmunoTech Inc..

Write a review
Explore

Similar companies

Browse all →